A stitch in time: could a device make abdominal closure safer?
NCT ID NCT07766044
First seen Aug 14, 2026 · Last updated Sep 03, 2026 · Updated 2 times
Summary
This trial compares two ways of closing the abdomen after open colorectal surgery: a device-assisted method (SutureTOOL) versus the traditional manual technique. The goal is to see if the device helps reduce the chance of an incisional hernia forming within one year. Participants are adults undergoing elective surgery through a midline incision for colorectal disease. The study also tracks short-term issues like wound infections and wound separation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A device-assisted closure technique using the SutureTOOL device versus manual closure with standard needle driver and curved needle.
- What this could lead to
- If successful, this could point toward a standardized closure method that reduces incisional hernias and other abdominal wall complications after open colorectal surgery.
- What could go wrong
- This is a single study with a limited number of participants, and results may not apply to all patients. The device may not significantly reduce hernia rates compared to careful manual closure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 218 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \>18 years of age * Patients selected for elective surgical procedure through a midline incision due to colorectal disease Exclusion Criteria: * Previous surgery including the midline * Previous hernia including the midline * Collagen disease * Disseminated disease at the time of surgery * Life expectancy less than 1 year.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Helsingborg hospital
RECRUITINGHelsingborg, Skåne County, 251 87, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers